New immune therapy drug enters human testing for tough cancers
NCT ID NCT05082610
Summary
This first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) in 48 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check for side effects and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Smilow Cancer Hospital - Yale New Heaven Health
New Haven, Connecticut, 06511, United States
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
The City of Hope National Medical Center
Duarte, California, 91010, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UTSW Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.